

Table SI. Baseline treatment in patients with moderate to severe psoriasis before undergoing bariatric surgery (surgery group), and matched patients not undergoing bariatric surgery (control group)

| Treatment | Surgery group <i>n</i> =50 | Control group <i>n</i> =91 |
|--------------|-------------------------------|-------------------------------|
| | <i>n</i> (%) | <i>n</i> (%) |
| Acitretin | 1 (2) | 2 (2.2) |
| Adalimumab | 13 (26) | 15 (16.5) |
| Apremilast | 0 (0) | 1 (1.1) |
| Ciclosporin | 2 (4.0) | 1 (1.1) |
| Efalizumab | 0 (0.0) | 1 (1.1) |
| Etanercept | 6 (12.0) | 8 (8.8) |
| Infliximab | 3 (6.0) | 4 (4.4) |
| Methotrexate | 23 (46.0) | 50 (54.9) |
| Secukinumab | 2 (4.0) | 0 (0) |
| Ustekinumab | 3 (6.0) | 7 (7.7) |